Psyadon Pharmaceuticals Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

Psyadon Pharmaceuticals General Information

Description

Developer of medicinal drugs intended to be used for treating psychiatric and neurodegenerative diseases. The company's medicinal drugs are focused on discovering, developing and marketing drugs, Ecopipam which selectively blocks the actions of the neurotransmitter dopamine at the D1 subtype in the brain, enabling targeted patients to help them get a cure who previously have no other therapeutic options.

Contact Information

Formerly Known As
Ruxton Pharmaceuticals
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 20451 Seneca Meadows Parkway
  • Germantown, MD 20876
  • United States
+1 (301)
Primary Industry
Drug Discovery
Corporate Office
  • 20451 Seneca Meadows Parkway
  • Germantown, MD 20876
  • United States
+1 (301)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Psyadon Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 14-Aug-2018 Completed Clinical Trials - Phase 2
4. Debt - General 18-Feb-2015 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A1) 12-Nov-2008 Completed Startup
2. Accelerator/Incubator 21-Feb-2005 $5.2M Completed Startup
1. Early Stage VC (Series A) 26-Jul-2004 $5.2M $5.2M Completed Startup
To view Psyadon Pharmaceuticals’s complete valuation and funding history, request access »

Psyadon Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A1
To view Psyadon Pharmaceuticals’s complete cap table history, request access »

Psyadon Pharmaceuticals Patents

Psyadon Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2015058053-A1 Fused benzazepines for treatment of stuttering Inactive 18-Oct-2013
AU-2013289922-A1 Fused benzazepines for treatment of tourette's syndrome Active 12-Jul-2012
AU-2013289922-B2 Fused benzazepines for treatment of tourette's syndrome Active 12-Jul-2012
WO-2014012034-A1 Fused benzazepines for treatment of tourette's syndrome Inactive 12-Jul-2012
WO-2014012063-A1 Pharmaceutical dosage forms comprising ecopipam free base or pharmaceutically acceptable salts thereof Inactive 12-Jul-2012 A61K9/5084
To view Psyadon Pharmaceuticals’s complete patent history, request access »

Psyadon Pharmaceuticals Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Aberdare Ventures Venture Capital Minority
Domain Associates Venture Capital Minority
Maryland Industrial Partnerships University
New Enterprise Associates Venture Capital Minority
To view Psyadon Pharmaceuticals’s complete investors history, request access »

Psyadon Pharmaceuticals FAQs

  • When was Psyadon Pharmaceuticals founded?

    Psyadon Pharmaceuticals was founded in 2004.

  • Where is Psyadon Pharmaceuticals headquartered?

    Psyadon Pharmaceuticals is headquartered in Germantown, MD.

  • What industry is Psyadon Pharmaceuticals in?

    Psyadon Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Psyadon Pharmaceuticals a private or public company?

    Psyadon Pharmaceuticals is a Private company.

  • What is Psyadon Pharmaceuticals’s current revenue?

    The current revenue for Psyadon Pharmaceuticals is .

  • How much funding has Psyadon Pharmaceuticals raised over time?

    Psyadon Pharmaceuticals has raised $13.2M.

  • Who are Psyadon Pharmaceuticals’s investors?

    Aberdare Ventures, Domain Associates, Maryland Industrial Partnerships, and New Enterprise Associates have invested in Psyadon Pharmaceuticals.

  • When was Psyadon Pharmaceuticals acquired?

    Psyadon Pharmaceuticals was acquired on 14-Aug-2018.

  • Who acquired Psyadon Pharmaceuticals?

    Psyadon Pharmaceuticals was acquired by Emalex Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process